Lars Ehlers
Aalborg Universitet
H-index: 35
Europe-Denmark
Top articles of Lars Ehlers
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Dose-reduction trials in oncology—aiming for less toxicity and better quality of life at lower costs | Kim Theilgaard-Mönch Lars Holger Ehlers | 2024/2 | |
Healthcare costs at the end of life for patients with non-cancer diseases and cancer in Denmark | PharmacoEconomics-Open | Anne Høy Seemann Vestergaard Lars Holger Ehlers Mette Asbjoern Neergaard Christian Fynbo Christiansen Jan Brink Valentin | 2023/9 |
Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms | Infectious diseases and therapy | Olivia Dybro Baek Camilla K Hjermitslev Line Dyreborg Simon MD Baunwall Katrine L Høyer | 2023/5 |
Does a corticosteroid injection plus exercise or exercise alone add to the effect of patient advice and a heel cup for patients with plantar fasciopathy? A randomised clinical … | British Journal of Sports Medicine | Henrik Riel Bill Vicenzino Jens Lykkegaard Olesen Martin Bach Jensen Lars Holger Ehlers | 2023/9/1 |
Participatory research: a priority setting partnership for chronic musculoskeletal pain in Denmark | Scandinavian Journal of Pain | Kristian D Lyng Jesper B Larsen Kathryn A Birnie Jennifer Stinson Morten S Hoegh | 2023/4/25 |
Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations | Blood advances | Matilde Slot Carsten Utoft Niemann Lars Holger Ehlers Emelie Curovic Rotbain | 2023/8/8 |
EE584 Is Point-of-Care Testing in Emergency Departments Cost-Effective? A Systematic Literature Review | J Andreasen JJ Larsen LH Ehlers | 2023/12/1 | |
Catalog of EQ-5D-3L Health-related quality-of-life scores for 199 chronic conditions and health risks in Denmark | MDM Policy & Practice | Michael Falk Hvidberg Karin Dam Petersen Michael Davidsen Flemming Witt Udsen Anne Frølich | 2023/4 |
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy | The European Journal of Health Economics | Lars Børty Rasmus F Brøndum Heidi S Christensen Charles Vesteghem Marianne Severinsen | 2023/8 |
PT23 Is It Possible to Estimate the Welfare Economic Loss to Society of Not Having Value-Based Differential Pricing for Multi-Indication Pharmaceuticals: An Empirical Analysis … | Value in Health | LH Ehlers CR Birch | 2023/12/1 |
Cost of non‐communicable diseases in people living with HIV in the Central Denmark Region | HIV medicine | Lars Holger Ehlers Flemming Axelsen Thomas Bøjer Rasmussen Jens Dollerup Nils Abild Jespersen | 2023/4 |
Danish population health measured by the EQ-5D-5L | Scandinavian journal of public health | Morten B Jensen Cathrine E Jensen Claire Gudex Kjeld M Pedersen Sabrina S Sørensen | 2023/3 |
A systematic review of cost-effectiveness studies of newer non-insulin antidiabetic drugs: Trends in decision-analytical models for modelling of type 2 diabetes mellitus | Henrik Vitus Bering Laursen Emmelie Ploug Jørgensen Peter Vestergaard Lars Holger Ehlers | 2023/11 | |
What is known and what is still unknown within chronic musculoskeletal pain? A systematic evidence and gap map | Pain | Kristian D Lyng Chris Djurtoft Malene K Bruun Mads N Christensen Rikke E Lauritsen | 2023/7/1 |
The analogue substitution model: Introducing competition in the absence of generic substitution in Danish hospitals | Health Policy | Elisabeth Christensen Niels Christian Hirsch Jonas Valbjørn Andersen Lars Holger Ehlers | 2022/9/1 |
Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017–2020 | Journal of pharmaceutical policy and practice | Lars Holger Ehlers Morten B Jensen Henrik Schack | 2022/12/31 |
Cost effectiveness of patient self-managed warfarin compared with direct oral anticoagulants in atrial fibrillation: an economic evaluation in a Danish healthcare sector setting | PharmacoEconomics-Open | Sabine Michelsen Raunbak Anne Sig Sørensen Louise Hansen Flemming Skjøth Torben Bjerregaard Larsen | 2022/7 |
EE200 A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs (NNIADS): Trends in Decision-Analytical Models (DAM) for Modelling of Type 2 … | H Laursen EP Jørgensen P Vestergaard LH Ehlers | 2022/12/1 | |
Economic evaluation alongside a randomized controlled trial of blended cognitive-behavioral therapy for patients suffering from major depressive disorder | Internet interventions | Astrid Langergaard Kim Mathiasen Jesper Søndergaard Sabrina S Sørensen Sidsel L Laursen | 2022/4/1 |
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark | Diabetes Therapy | Reimar W Thomsen Lotte WB Christensen Johnny Kahlert Jakob S Knudsen Anastasia Ustyugova | 2022/12 |
